GDF15 Neutralization Ameliorates Muscle Atrophy and Exercise Intolerance in a Mouse Model of Mitochondrial Myopathy
Our findings highlight the potential of GDF15 neutralization with a monoclonal antibody as a therapeutic avenue to enhance physical performance and mitigate adverse clinical outcomes in patients with PMM.
Authors
- Srinath Jagarlapudi
- Stephen E Flaherty (ORCID: https://orcid.org/0000-0002-5050-6451)
- Anthony Rinaldi
- Mary E. Piper (ORCID: https://orcid.org/0000-0003-2699-3840)
- Shoh Asano (ORCID: https://orcid.org/0000-0002-9201-1350)
- LouJin Song (ORCID: https://orcid.org/0000-0002-1646-8121)
- Abdul Q. Sheikh
- Bina Albuquerque
- Zhidan Wu (ORCID: https://orcid.org/0000-0001-7289-9420)
- Evanthia Pashos
- Trenton T. Ross
- John C. Stansfield
- Xian Chen (ORCID: https://orcid.org/0000-0002-1757-1040)
- Bei Zhang (ORCID: https://orcid.org/0000-0002-6355-185X)
- Dinesh Hirenallur-Shanthappa
Institutions
- Eli Lilly (United States) (US)
- Pfizer (United States) (US)
- Novo Nordisk (United States) (US)
- Vertex Pharmaceuticals (United States) (US)
Publication Details
- Journal
- Journal of Cachexia Sarcopenia and Muscle
- Published
- 2025-02-01
- DOI
- https://doi.org/10.1002/jcsm.13715
- Citations
- 14
- Primary Topic
- GDF15 and Related Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 23.35
Funders
- Pfizer